Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory phase 2 study of intraperitoneal albumin-bound paclitaxel as neoadjuvant therapy in unresectable stage III primary ovarian high-grade serous adenocarcinoma
ChiCTR2000036809Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel in Serous Papillary Cystadenocarcinoma, sponsored by Fudan University Shanghai Cancer Center. Primary endpoints: Incidence of adverse events and Treatment completion rate. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
paclitaxel
03
Conditions
Serous Papillary Cystadenocarcinoma
Beyond the preview
Go deeper on ChiCTR2000036809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036809.